FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2393828952> ?p ?o ?g. }

• W2393828952 endingPage "360" @default.
• W2393828952 startingPage "357" @default.
• W2393828952 abstract "Abstract In this phase I/II study, 9 patients with myelodysplastic syndromes (MDS) were treated with interleukin-3 (IL-3) followed by granulocyte- macrophage colony-stimulating factor (GM-CSF). Each treatment cycle was 28 days long and administered as follows: 1 microgram/kg/d IL-3 on days 1 through 7 and 3 micrograms/kg/d GM-CSF for days 8 through 21, followed by a 7-day rest period. IL-3 dose escalations were planned, but the dose of GM-CSF was fixed. Three patients had refractory anemia, 4 had refractory anemia with ringed sideroblasts, and 2 had refractory anemia with excess blasts. Six patients were dependent on red blood cell transfusions, 1 on platelet transfusions, and 2 on both. The absolute neutrophil count improved in 7 (77%) patients and the platelet count improved in 3 (33%) patients during therapy. Hemoglobin levels were unchanged. A clinically relevant response was seen in only 1 patient with thrombocytopenia, and he received five cycles of therapy. The neutrophil count decreased in 2 patients and the platelet count decreased in 4 patients during treatment. The toxicity of the treatment was significant. In the first cohort of 3 patients, 1 patient developed supraventricular tachycardia and congestive heart failure. In the second group, 1 patient developed progressive granulocytopenia and died of gram-negative septicemia. Because of the disparate toxicity, 3 more patients were treated at the same dose level. One of these experienced a high fever and bone pain requiring hospitalization. Because of these adverse effects, the IL-3 dose was not escalated and all patients received 1 microgram/kg/d for 7 days. We believe that sequential therapy with IL-3 and GM-CSF at these dose levels causes unacceptable toxicity in patients with MDS. The major toxic events occurred during weeks 4 and 5 after starting treatment and may have been primarily caused by GM-CSF therapy. Although neutrophil counts improve in most patients, the effect on red blood cells and platelets is minimal. At present, this form of therapy remains problematic and appears to have a limited potential in the management of MDS." @default.
• W2393828952 created "2016-06-24" @default.
• W2393828952 creator A5009574158 @default.
• W2393828952 creator A5018275922 @default.
• W2393828952 creator A5054425800 @default.
• W2393828952 creator A5075566772 @default.
• W2393828952 date "1994-01-15" @default.
• W2393828952 modified "2023-10-16" @default.
• W2393828952 title "A phase I/II study of sequential interleukin-3 and granulocyte- macrophage colony-stimulating factor in myelodysplastic syndromes" @default.
• W2393828952 cites W1973034088 @default.
• W2393828952 cites W1991796424 @default.
• W2393828952 cites W2015627245 @default.
• W2393828952 cites W2031788307 @default.
• W2393828952 cites W2050214747 @default.
• W2393828952 cites W2071595697 @default.
• W2393828952 cites W2147530468 @default.
• W2393828952 cites W2161626968 @default.
• W2393828952 cites W2256927828 @default.
• W2393828952 cites W2262642532 @default.
• W2393828952 cites W2263914605 @default.
• W2393828952 cites W226629945 @default.
• W2393828952 cites W2399254225 @default.
• W2393828952 cites W2406378945 @default.
• W2393828952 cites W2410421515 @default.
• W2393828952 cites W2411230816 @default.
• W2393828952 cites W2414097276 @default.
• W2393828952 cites W2419306110 @default.
• W2393828952 cites W2425605911 @default.
• W2393828952 cites W2428924142 @default.
• W2393828952 cites W2432867267 @default.
• W2393828952 cites W2434846429 @default.
• W2393828952 cites W2466221235 @default.
• W2393828952 cites W2607721102 @default.
• W2393828952 cites W318176031 @default.
• W2393828952 cites W1969280967 @default.
• W2393828952 cites W1983392832 @default.
• W2393828952 doi "https://doi.org/10.1182/blood.v83.2.357.357" @default.
• W2393828952 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/8286736" @default.
• W2393828952 hasPublicationYear "1994" @default.
• W2393828952 type Work @default.
• W2393828952 sameAs 2393828952 @default.
• W2393828952 citedByCount "38" @default.
• W2393828952 countsByYear W23938289522012 @default.
• W2393828952 countsByYear W23938289522021 @default.
• W2393828952 crossrefType "journal-article" @default.
• W2393828952 hasAuthorship W2393828952A5009574158 @default.
• W2393828952 hasAuthorship W2393828952A5018275922 @default.
• W2393828952 hasAuthorship W2393828952A5054425800 @default.
• W2393828952 hasAuthorship W2393828952A5075566772 @default.
• W2393828952 hasBestOaLocation W23938289521 @default.
• W2393828952 hasConcept C121332964 @default.
• W2393828952 hasConcept C126322002 @default.
• W2393828952 hasConcept C141071460 @default.
• W2393828952 hasConcept C142424586 @default.
• W2393828952 hasConcept C197934379 @default.
• W2393828952 hasConcept C2776139714 @default.
• W2393828952 hasConcept C2776694085 @default.
• W2393828952 hasConcept C2777063308 @default.
• W2393828952 hasConcept C2777767877 @default.
• W2393828952 hasConcept C2778248108 @default.
• W2393828952 hasConcept C2780007613 @default.
• W2393828952 hasConcept C2780817109 @default.
• W2393828952 hasConcept C29730261 @default.
• W2393828952 hasConcept C71924100 @default.
• W2393828952 hasConcept C74133956 @default.
• W2393828952 hasConcept C87355193 @default.
• W2393828952 hasConcept C89560881 @default.
• W2393828952 hasConcept C90924648 @default.
• W2393828952 hasConceptScore W2393828952C121332964 @default.
• W2393828952 hasConceptScore W2393828952C126322002 @default.
• W2393828952 hasConceptScore W2393828952C141071460 @default.
• W2393828952 hasConceptScore W2393828952C142424586 @default.
• W2393828952 hasConceptScore W2393828952C197934379 @default.
• W2393828952 hasConceptScore W2393828952C2776139714 @default.
• W2393828952 hasConceptScore W2393828952C2776694085 @default.
• W2393828952 hasConceptScore W2393828952C2777063308 @default.
• W2393828952 hasConceptScore W2393828952C2777767877 @default.
• W2393828952 hasConceptScore W2393828952C2778248108 @default.
• W2393828952 hasConceptScore W2393828952C2780007613 @default.
• W2393828952 hasConceptScore W2393828952C2780817109 @default.
• W2393828952 hasConceptScore W2393828952C29730261 @default.
• W2393828952 hasConceptScore W2393828952C71924100 @default.
• W2393828952 hasConceptScore W2393828952C74133956 @default.
• W2393828952 hasConceptScore W2393828952C87355193 @default.
• W2393828952 hasConceptScore W2393828952C89560881 @default.
• W2393828952 hasConceptScore W2393828952C90924648 @default.
• W2393828952 hasIssue "2" @default.
• W2393828952 hasLocation W23938289521 @default.
• W2393828952 hasOpenAccess W2393828952 @default.
• W2393828952 hasPrimaryLocation W23938289521 @default.
• W2393828952 hasRelatedWork W1994364791 @default.
• W2393828952 hasRelatedWork W2009664834 @default.
• W2393828952 hasRelatedWork W2037087317 @default.
• W2393828952 hasRelatedWork W2039777360 @default.
• W2393828952 hasRelatedWork W2165047565 @default.
• W2393828952 hasRelatedWork W2380496346 @default.
• W2393828952 hasRelatedWork W2410418099 @default.
• W2393828952 hasRelatedWork W2413360557 @default.

• next